cdmo capex requirements
Why Semaglutide's CAPEX Harms Your Bottom Line
Semaglutide API production is projected to exceed 500 kg per day by 2035, reflecting a 12% annual growth since 2024. This surge is driven by rising demand for GLP-1 obesity treatments and expanding CDMO capacity worldwide. Medical Disclaimer: This article is for informational purposes only and does not constitute medical